Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jakob Ribbing

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
British Journal of Clinical Pharmacology|January 18, 2013
Predicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary diseasePaul Matthias Diderichsen, Eugène Cox, Steven W Martin, et al.
Journal of Clinical Pharmacology|May 22, 2025
Population Pharmacokinetics and Exposure-Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn's DiseaseAnita Moein, Jakob Ribbing, Moustafa M A Ibrahim, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 25, 2012
Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary diseaseJace C Nielsen, Matthew M Hutmacher, Adriaan Cleton, et al.
European Journal of Clinical Pharmacology|March 3, 2012
Placebo effect model in asthma clinical studies: longitudinal meta-analysis of forced expiratory volume in 1 secondXipei Wang, Dewei Shang, Jakob Ribbing, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 5, 2022
Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitisNastya Kassir, Rui Zhu, Anita Moein, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 19, 2022
Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitisAnita Moein, Tong Lu, Siv Jönsson, et al.
Journal of Clinical Pharmacology|December 29, 2021
Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe AsthmaNaoki Kotani, Michael Dolton, Robin J Svensson, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 4, 2021
Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnairesRobin J Svensson, Jakob Ribbing, Naoki Kotani, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 3, 2024
Covariate modeling in pharmacometrics: General points for considerationKinjal Sanghavi, Jakob Ribbing, James A Rogers, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
British Journal of Clinical Pharmacology|January 18, 2013
Predicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary diseasePaul Matthias Diderichsen, Eugène Cox, Steven W Martin, et al.
Journal of Clinical Pharmacology|May 22, 2025
Population Pharmacokinetics and Exposure-Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn's DiseaseAnita Moein, Jakob Ribbing, Moustafa M A Ibrahim, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 25, 2012
Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary diseaseJace C Nielsen, Matthew M Hutmacher, Adriaan Cleton, et al.
European Journal of Clinical Pharmacology|March 3, 2012
Placebo effect model in asthma clinical studies: longitudinal meta-analysis of forced expiratory volume in 1 secondXipei Wang, Dewei Shang, Jakob Ribbing, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 5, 2022
Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitisNastya Kassir, Rui Zhu, Anita Moein, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 19, 2022
Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitisAnita Moein, Tong Lu, Siv Jönsson, et al.
Journal of Clinical Pharmacology|December 29, 2021
Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe AsthmaNaoki Kotani, Michael Dolton, Robin J Svensson, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 4, 2021
Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnairesRobin J Svensson, Jakob Ribbing, Naoki Kotani, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 3, 2024
Covariate modeling in pharmacometrics: General points for considerationKinjal Sanghavi, Jakob Ribbing, James A Rogers, et al.
Pageof 2